Data / Drug companies / Aphena Pharma Solutions - Tennessee, LLC
Aphena Pharma Solutions - Tennessee, LLC: 69 products in the FDA NDC directory, labeler code 43353
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Aphena Pharma Solutions - Tennessee, LLC (labeler code 43353) lists 69 products in the FDA National Drug Code Directory, covering 42 finished drugs by generic name. By type: 67 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 20, 2017.
The request: Watch Aphena Pharma Solutions - Tennessee, LLC (FDA labeler code 43353): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 43353
- Products in commercial distribution
- 69
- Packages
- 252
- Finished drugs by generic name
- 42
- Prescription products
- 67
- Over the counter products
- 2
- Controlled substance products
- Schedule IV 5, Schedule V 2
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- January 12, 1973
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 62 | 89.9% |
| Authorized generics (NDA) | 3 | 4.3% |
| New drug applications (NDA) | 3 | 4.3% |
| Over the counter monograph drugs | 1 | 1.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 67 | 97.1% |
| Over the counter drugs | 2 | 2.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 46 | 66.7% |
| Capsule | 8 | 11.6% |
| Tablet, film coated | 6 | 8.7% |
| Tablet, extended release | 5 | 7.2% |
| Capsule, liquid filled | 2 | 2.9% |
| Tablet, delayed release | 1 | 1.4% |
| Capsule, delayed release | 1 | 1.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Diphenoxylate Hydrochloride and Atropine Sulfate | 43353-594 | Tablet | Generic drugs (ANDA) | June 20, 2017 |
| Valproic Acid | 43353-279 | Capsule, liquid filled | Generic drugs (ANDA) | July 15, 2016 |
| Naproxen | 43353-218 | Tablet | Generic drugs (ANDA) | June 10, 2016 |
| Naproxen | 43353-216 | Tablet | Generic drugs (ANDA) | June 10, 2016 |
| Naproxen | 43353-211 | Tablet | Generic drugs (ANDA) | June 10, 2016 |
| HydrALAZINE Hydrochloride | 43353-205 | Tablet | Generic drugs (ANDA) | May 20, 2016 |
| Oxybutynin Chloride Extended Release | 43353-322 | Tablet, extended release | Generic drugs (ANDA) | March 9, 2016 |
| Oxybutynin Chloride Extended Release | 43353-284 | Tablet, extended release | Generic drugs (ANDA) | March 9, 2016 |
| Oxybutynin Chloride Extended Release | 43353-282 | Tablet, extended release | Generic drugs (ANDA) | March 9, 2016 |
| Tacrolimus | 43353-317 | Capsule | Generic drugs (ANDA) | November 18, 2015 |
| Ergocalciferol | 43353-238 | Capsule, liquid filled | Generic drugs (ANDA) | July 23, 2015 |
| Sodium bicarbonate | 43353-162 | Tablet | Over the counter monograph drugs | May 1, 2015 |
| Warfarin Sodium | 43353-054 | Tablet | Generic drugs (ANDA) | April 8, 2015 |
| Warfarin Sodium | 43353-053 | Tablet | Generic drugs (ANDA) | April 8, 2015 |
| Warfarin Sodium | 43353-033 | Tablet | Generic drugs (ANDA) | April 8, 2015 |
| Warfarin Sodium | 43353-029 | Tablet | Generic drugs (ANDA) | April 8, 2015 |
| Warfarin Sodium | 43353-023 | Tablet | Generic drugs (ANDA) | April 8, 2015 |
| Warfarin Sodium | 43353-021 | Tablet | Generic drugs (ANDA) | April 8, 2015 |
| Gabapentin | 43353-081 | Capsule | Generic drugs (ANDA) | March 17, 2014 |
| Lisinopril | 43353-301 | Tablet | Generic drugs (ANDA) | March 15, 2014 |
| Lisinopril | 43353-298 | Tablet | Generic drugs (ANDA) | March 15, 2014 |
| Lisinopril | 43353-271 | Tablet | Generic drugs (ANDA) | March 15, 2014 |
| Lisinopril | 43353-270 | Tablet | Generic drugs (ANDA) | March 15, 2014 |
| Lisinopril | 43353-009 | Tablet | Generic drugs (ANDA) | March 15, 2014 |
| Carbamazepine | 43353-953 | Tablet | Generic drugs (ANDA) | March 7, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.